Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders

BACKGROUND: Lubiprostone is a ClC-2 chloride channel activator approved for the treatment of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC) in adults and irritable bowel syndrome with constipation (IBS-C) in women. Lubiprostone is generally well tolerated, with nausea be...

Descripción completa

Detalles Bibliográficos
Autores principales: Cryer, Byron, Drossman, Douglas A., Chey, William D., Webster, Lynn, Habibi, Sepideh, Wang, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694526/
https://www.ncbi.nlm.nih.gov/pubmed/28849329
http://dx.doi.org/10.1007/s10620-017-4680-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694526/
https://www.ncbi.nlm.nih.gov/pubmed/28849329
http://dx.doi.org/10.1007/s10620-017-4680-1

Ejemplares similares